<DOC>
	<DOCNO>NCT00336219</DOCNO>
	<brief_summary>The aim study compare investigator patient-assessed gastroesophageal reflux disease symptoms patient erosive GERD endoscopic-negative GERD ( enGERD ) . An endoscopy perform study start study end . During study , patient complete patient-orientated , self-assessed reflux questionnaire ( ReQuestâ„¢ questionnaire ) . The study duration consist baseline period ( 8 day ) treatment period ( 28 day ) . Pantoprazole ( tablet ) administer daily one dose level . The study provide data safety tolerability pantoprazole .</brief_summary>
	<brief_title>Symptom Assessment Adult Patients With Erosive GERD ( Gastroesophageal Reflux Disease ) enGERD ( Endoscopic-negative GERD ) After Treatment With Pantoprazole ( BY1023/M3-343 )</brief_title>
	<detailed_description />
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Pantoprazole</mesh_term>
	<criteria>Main Written inform consent Outpatients History GERDrelated symptoms least 6 month prior study inclusion Endoscopically confirm erosive GERD nonerosive GERD Main Acute peptic ulcer and/or ulcer complication PPIs last 7 day prior study start Systemic glucocorticoid nonsteroidal antiinflammatory drug include COX2 inhibitor last 28 day prior study start ; except regular intake acetylsalicylic acid daily dose 163 mg/day Intake PPIs combination antibiotic eradication H. pylorus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>GERD</keyword>
	<keyword>Pantoprazole</keyword>
</DOC>